Form 8-K - Current report:
SEC Accession No. 0001213900-25-065655
Filing Date
2025-07-18
Accepted
2025-07-18 16:05:39
Documents
13
Period of Report
2025-07-18
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249528-8k_cero.htm   iXBRL 8-K 34042
  Complete submission text file 0001213900-25-065655.txt   247402

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cero-20250718.xsd EX-101.SCH 3829
3 XBRL DEFINITION FILE cero-20250718_def.xml EX-101.DEF 26720
4 XBRL LABEL FILE cero-20250718_lab.xml EX-101.LAB 36917
5 XBRL PRESENTATION FILE cero-20250718_pre.xml EX-101.PRE 25344
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0249528-8k_cero_htm.xml XML 6036
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251134550
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)